“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in EUR
Last close As at 25/03/2023
EUR202.50
▲ −5.00 (−2.41%)
Market capitalisation
EUR1,444m
HBM Healthcare Investments (formerly HBM BioVentures, renamed in 2012) is a Swiss investment company that aims to generate long-term capital gains by investment in private and public companies in the human medicine, biotech, medtech and diagnostic sectors, and related areas. It invests worldwide, predominantly in later-stage private companies (either directly or through funds) and publicly listed holdings, many of which began as private equity investments.
Investment Companies
Investment Companies
Investment Companies
Investment Companies
Director, Investment Trusts
Andreas Wicki
CEO
Erwin Troxler
CFO
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (7.5) | 1.3 | (26.1) |
| Relative | (3.1) | 1.2 | (16.4) |
| 52 week high/low | €281.5/€192.2 |
HBM Healthcare Investments (HBMN) posted its first NAV loss in a decade for FY22 (ended 31 March), but, as shown in the chart below, its long-term performance record remains very impressive. The recent fall in the share price from a premium to a discount to NAV (10.0% at 20 May) could present an opportunity for long-term investors who, like HBMN’s management team, remain convinced of the long-term opportunities afforded by careful investment in the healthcare and biotechnology space. HBMN is unusual among its peers in offering a portfolio made up of private companies, listed equities and funds, broadly spread by geography and clinical focus, with a high distribution policy (current yield of 3.8%).
Investment Companies
Get access to the very latest content matched to your personal investment style.
